Home / Business News / Intec Pharma Enters Research Collaboration Agreement With Merck for the Accordion Pill Platform

Intec Pharma Enters Research Collaboration Agreement With Merck for the Accordion Pill Platform

NEW YORK, May 16, 2019 /PRNewswire/ –Intec Pharma Ltd. (NASDAQ: NTEC) (“Intec” or “the Company”) today announces it has entered into an agreement with Merck, known as MSD outside the United States and Canada, to explore using the Accordion Pill® (AP) platform for an undisclosed development program.

“We are very excited to collaborate with Merck,” said Jeffrey A. Meckler, Vice Chairman and Chief Executive Officer of Intec Pharma. “Through partnerships such as this, we continue to evaluate how the Accordion Pill’s innovative gastric retention and controlled drug release properties may be used to enhance therapeutic attributes.”

“We believe this program, as well as our ongoing collaboration with Novartis, paves the way for other new collaborations to further validate the AP platform and confirms our technical abilities to build custom APs. Importantly, these new programs offer the opportunity to pursue novel additions to our product and intellectual property portfolio,” concluded Mr. Meckler.

About Intec Pharma Ltd.

Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. The Company’s Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism. The Company’s product pipeline includes two product candidates in clinical trial stages: Accordion Pill Carbidopa/Levodopa, or AP-CD/LD, which is in late-stage Phase 3 development for the treatment of Parkinson’s disease symptoms in advanced Parkinson’s disease patients, and AP-cannabinoids, an Accordion Pill to deliver either or both of the primary cannabinoids contained in Cannabis sativa, cannabidiol (CBD) and tetrahydrocannabinol (THC) for various pain indications. In addition, the Company has a feasibility agreement for the development of a custom-designed Accordion Pill for a proprietary compound with Novartis Pharmaceuticals.

For more information, visit www.intecpharma.com. Intec Pharma routinely posts information that may be important to investors in the Investor Relations section of its website.

Check Also

Actelion and Owlstone Medical Collaborate to Develop a Breath-Based Test to Help Facilitate Early Detection of Pulmonary Hypertension

CAMBRIDGE, England–(BUSINESS WIRE)–Owlstone Medical, the global leader in Breath Biopsy® for applications in early disease …